.
New Delhi, April 26 (MondayMirror.com) The Drugs Controller General of India (DCGI) on Tuesday approved the restricted emergency use authorisation (EUA) to Bharat Biotech’s Covaxin for children between the age of 6-12 years, sources said.
The DGCI has asked vaccine manufacturer to submit safety data including the data on adverse event with due analysis every 15 days for the first two months and monthly thereafter upto 5 months, said the source familiar with the development.
This development comes after the Subject Expert Committee (SEC) discussed recommendations for the restricted emergency use of Covaxin in children aged between 2-12 years.
However, the SEC, after a meeting on Thursday, had recommended restricted emergency use of Biological E’s Covid-19 vaccine, Corbevax, in children aged 5-12 years.
Source: IANS
EDUTHON 6.0 brought more than 1,200 school leaders, educators, policymakers, entrepreneurs, educationists and industry representatives…
The Confederation of Indian Industry (CII), Chandigarh, organised an interactive session on the recommendations of…
Aakash Education Services Limited, one of India’s leading test- preparation providers, has announced the strengthening…
District receives honours for organising 90 camps in which over 6,000 units of blood were…
The second day of the three-day 48th Annual Chandigarh Sangeet Sammelan, organised by the Indian…
Product quality, a missing shutter, and uncertainty over replacement raise concerns about after-sales service. CHANDIGARH…